Style de citation APA (7e éd.)

Marques, P., Domingo, E., Rubio, A., Martinez-Hervás, S., Ascaso, J. F., Piqueras, L., . . . Sanz, M. (2022). Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players. Elsevier.

Style de citation Chicago (17e éd.)

Marques, Patrice, Elena Domingo, Arantxa Rubio, Sergio Martinez-Hervás, Juan F. Ascaso, Laura Piqueras, José T. Real, et Maria-Jesus Sanz. Beneficial Effects of PCSK9 Inhibition with Alirocumab in Familial Hypercholesterolemia Involve Modulation of New Immune Players. Elsevier, 2022.

Style de citation MLA (8e éd.)

Marques, Patrice, et al. Beneficial Effects of PCSK9 Inhibition with Alirocumab in Familial Hypercholesterolemia Involve Modulation of New Immune Players. Elsevier, 2022.